Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic
- 4 June 2022
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 4 (5) , 100673
Abstract
No abstract availableKeywords
Funding Information
- Emory Medical Care Foundation
This publication has 18 references indexed in Scilit:
- Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort studyAmerican Journal of Obstetrics and Gynecology, 2021
- The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studiesCell, 2021
- Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionmedRxiv, 2021
- Coronavirus Disease 2019 (COVID-19) Treatment Guidelines2021
- Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)Obstetrics & Gynecology, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- COVID‐19‐related disease severity in pregnancyAmerican Journal of Reproductive Immunology, 2020
- Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020